R&D spending increased 37.1% to $301.1M in 2025 for next-gen products

{
  "signal_id": "305a4fcd-3bdd-4d01-8ec9-846425c77c31",
  "signal_type": "sec-10k",
  "signal_subtype": "capexIncrease",
  "detected_at": "2026-02-24T09:29:25.523+00:00",
  "company": {
    "name": "Insulet",
    "domain": "insulet.com"
  },
  "data": {
    "detail": "The company is heavily investing in future products, including a fully closed-loop system, Omnipod 6, and new CGM integrations. This budget increase supports headcount growth and consulting costs for clinical trials and product development, indicating opportunities for R&D and clinical trial support vendors.",
    "metrics": {
      "pct": 0.371,
      "pct_context": "YoY increase in R&D spending",
      "dollar_context": "2025 Research and development expenses",
      "dollar_millions": 301.1
    },
    "summary": "R&D spending increased 37.1% to $301.1M in 2025 for next-gen products",
    "excerpts": "Research and development expenses increased $81.5 million, or 37.1%, to $301.1 million for 2025, compared with $219.6 million for 2024.",
    "relevance": 0.8,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1145197/000114519726000028/podd-20251231.htm",
    "filing_date": "2026-02-18",
    "filing_year": 2026,
    "fiscal_year_end": "12/31",
    "sales_relevance": "Budget available",
    "signal_category": "financial",
    "vendors_mentioned": [
      "Abbott Diabetes Care, Inc."
    ],
    "technologies_mentioned": [
      "closed loop AID system"
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/305a4fcd-3bdd-4d01-8ec9-846425c77c31 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"insulet.com","limit":20}'